Background: Effective and safe pharmacological approaches for atrial defibrillation offer several potential advantages over techniques like ablation. Pharmacological therapy is noninvasive, involving no risk associated with the procedure or resulting complications. Moreover, acute drug intervention with existing drugs is likely to be low cost and broadly accessible, thereby addressing a central tenet of health equity.
Objectives: This study aims to investigate ibutilide-mediated action potential prolongation to promote use-dependent effects of flecainide on Na channels by reducing the diastolic interval and, consequently, drug unbinding to reduce action potential excitability in atrial tissue and terminate re-entrant arrhythmia.
Methods: The authors utilize a modeling and simulation approach to predict the specific combinations of sodium- and potassium-channel blocking drugs to chemically terminate atrial re-entry.
Results: Computational modeling and simulation show that acute application of flecainide and ibutilide is a promising example of drug repurposing that may constitute a promising combination for chemical atrial defibrillation.
Conclusions: We predict the drug concentrations that promote efficacy of flecainide and ibutilide used in combination for atrial chemical defibrillation. We also predict the potential safety pharmacology impact of this drug combination on ventricular electrophysiology.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jacep.2024.08.009 | DOI Listing |
JACC Clin Electrophysiol
December 2024
Department of Physiology and Membrane Biology, Center for Precision Medicine and Data Science, School of Medicine, University of California-Davis, Davis, California, USA. Electronic address:
Background: Effective and safe pharmacological approaches for atrial defibrillation offer several potential advantages over techniques like ablation. Pharmacological therapy is noninvasive, involving no risk associated with the procedure or resulting complications. Moreover, acute drug intervention with existing drugs is likely to be low cost and broadly accessible, thereby addressing a central tenet of health equity.
View Article and Find Full Text PDFClin Cardiol
August 2024
Centre for Chronic & Complex Care Research, Blacktown Hospital, Western Sydney Local Health District, Blacktown, New South Wales, Australia.
Background: Atrial fibrillation (AF) and obesity coexist in approximately 37.6 million and 650 million people globally, respectively. The anatomical and physiological changes in individuals with obesity may influence the pharmacokinetic properties of drugs.
View Article and Find Full Text PDFCochrane Database Syst Rev
June 2024
Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Cardiovasc Drugs Ther
February 2024
Department of Emergency Medicine, Stony Brook University, Stony Brook, NY, USA.
Purpose: The available evidence to determine which antidysrhythmic drug is superior for pharmacologic cardioversion of recent-onset (onset within 48 h) atrial fibrillation (AF) is uncertain. We aimed to identify the safest and most effective agent for pharmacologic cardioversion of recent-onset AF in the emergency department.
Methods: We searched MEDLINE, Embase, and Web of Science from inception to February 21, 2023 (PROSPERO: CRD42018083781).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!